BioSapien Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$8M
- Investors
-
16
BioSapien General Information
Description
Developer of a three-dimensional printed drug delivery platform designed to deliver medicines in a localized, sustained manner for cancer indications. The company's platform offers products that are being designed with biodegradable mesh capable of the sustained delivery of small molecules and are affixable to delicate and complex anatomy, enabling healthcare professionals to achieve efficacy while decreasing toxicity by releasing drugs directly to a cancerous tumor site.
Contact Information
Website
www.biosapien.comCorporate Office
- 6076 Corte Del Cedro
- Carlsbad, CA 92011
- United States
Corporate Office
- 6076 Corte Del Cedro
- Carlsbad, CA 92011
- United States
BioSapien Timeline
BioSapien Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC | 07-Jul-2025 | $8M | Completed | Clinical Trials - Phase 1 | ||
| 7. Accelerator/Incubator | 01-Jan-2024 | Completed | Startup | |||
| 6. Accelerator/Incubator | Completed | Pre-Clinical Trials | ||||
| 5. Grant | 01-Oct-2021 | Completed | Pre-Clinical Trials | |||
| 4. Seed Round | 10-Aug-2021 | Completed | Pre-Clinical Trials | |||
| 3. Grant | 01-Jul-2021 | Completed | Pre-Clinical Trials | |||
| 2. Accelerator/Incubator | 12-Sep-2019 | $250K | $290K | Completed | Startup | |
| 1. Accelerator/Incubator | 21-Dec-2018 | $40K | $40K | Completed | Startup |
BioSapien Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed Prime | ||||||||
| Seed 3 | ||||||||
| Seed 2 | 527,000 | $0.000100 | $0.19 | $0.19 | 1x | $0.19 | 2% | |
| Seed 1 | 1,378,000 | $0.000100 | $0.09 | $0.09 | 1x | $0.09 | 5.22% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
BioSapien Comparisons
Industry
Financing
Details
BioSapien Competitors (41)
One of BioSapien’s 41 competitors is Focal Medical (Drug Delivery), a Formerly VC-backed company based in Cary, NC.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Focal Medical (Drug Delivery) | Formerly VC-backed | Cary, NC | ||||
| Xencor | Formerly VC-backed | Pasadena, CA | ||||
| Boundless Bio | Formerly VC-backed | San Diego, CA | ||||
| PanTher Therapeutics | Venture Capital-Backed | Austin, TX | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA |
BioSapien Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
BioSapien Patents
BioSapien Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026236691-A1 | Drug-eluting systems and methods of use thereof | Pending | 09-May-2025 | ||
| AU-2023268495-A1 | Drug-eluting surgical articles and methods of use thereof | Pending | 13-May-2022 | ||
| EP-4522238-A2 | Drug-eluting surgical articles and methods of use thereof | Pending | 13-May-2022 | ||
| EP-4522238-A4 | Drug-eluting surgical articles and methods of use thereof | Pending | 13-May-2022 | ||
| GB-202417670-D0 | Drug-eluting surgical articles and methods of use thereof | Pending | 13-May-2022 | A61K9/0024 |
BioSapien Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
BioSapien Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Dara Holdings | Real Estate | Minority | ||
| Global Ventures (Private Equity) | Venture Capital | Minority | ||
| Globivest | Venture Capital | Minority | ||
| Golden Gate Ventures | Venture Capital | Minority | ||
| SC Ventures | Corporate Venture Capital | Minority |
BioSapien FAQs
-
When was BioSapien founded?
BioSapien was founded in 2018.
-
Where is BioSapien headquartered?
BioSapien is headquartered in Carlsbad, CA.
-
What is the size of BioSapien?
BioSapien has 10 total employees.
-
What industry is BioSapien in?
BioSapien’s primary industry is Drug Delivery.
-
Is BioSapien a private or public company?
BioSapien is a Private company.
-
What is the current valuation of BioSapien?
The current valuation of BioSapien is .
-
What is BioSapien’s current revenue?
The current revenue for BioSapien is .
-
How much funding has BioSapien raised over time?
BioSapien has raised $10.1M.
-
Who are BioSapien’s investors?
Dara Holdings, Global Ventures (Private Equity), Globivest, Golden Gate Ventures, and SC Ventures are 5 of 16 investors who have invested in BioSapien.
-
Who are BioSapien’s competitors?
Focal Medical (Drug Delivery), Xencor, Boundless Bio, PanTher Therapeutics, and CytomX Therapeutics are some of the 41 competitors of BioSapien.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
